FluoroPharma Medical Inc

OTC:FPMI

FluoroPharma Medical, Inc. is a molecular imaging company, which engages in the research, development, and commercialization molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company is headquartered in Montclair, New Jersey and currently employs 4 full-time employees. The company went IPO on 2008-08-18. The firm operates through biopharmaceutical research and development segment. The company is focused on the development of cardiovascular imaging agents that can detect and assess acute and chronic forms of coronary artery disease (CAD). The company has two clinical-stage molecular imaging pharmaceutical product candidates: Flourine-18 (18-F) TPP (BFPET), which includes a ((18F)-labeled cationic lipophilic tetraphenylphosphonium ion (18-F TPP) as an imaging agent designed for use in stress-testing for patients with presumptive or proven CAD, and 18-F FCPHA (CardioPET), which includes Trans-9-(18F)-Fluoro-3, 4-Methyleneheptadecanoic Acid (18-F FCPHA) as a molecular imaging agent designed to assess myocardial blood flow and metabolism in patients with CAD.